We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Autophagy facilitates anticancer effect of 5-fluorouracil in HCT-116 cells.
- Authors
Jing-wen Yang; Qing-huai Zhang; Tong Liu; Yang, Jing-Wen; Zhang, Qing-Huai; Liu, Tong
- Abstract
<bold>Aim Of Study: </bold>The roles of autophagy performed in chemotherapy-induced cell death or proliferation inhibition were still in debate. In this study, we aimed to disclose the function of autophagy in chemotherapy of HCT-116 colon cells.<bold>Materials and Methods: </bold>Pharmacological and genetic methods were applied to induce and inhibit autophagy and elucidate the roles of autophagy performed in chemotherapy-induced proliferation inhibition and apoptosis. Autophagy was assessed by microtubule-associated protein light chain 3 (LC3) expression and monodansylcadaverine (MDC) staining.<bold>Results: </bold>After treatment with 5-fluorouracil (5-FU), HCT-116 cells showed typical autophagy as stained by MDC. Autophagy inhibitor (3-methyladenine [3-MA]) or inducer (rapamycin) was applied in combination with 5-FU, respectively. As evidenced by our data, 3-MA inhibited while rapamycin facilitated 5-FU-induced apoptosis and proliferation inhibition of HCT-116 cells. Consistently, 3-MA inhibited, while rapamycin facilitated 5-FU-induced expressions of Beclin1 and LC3B. Moreover, 3-MA inhibited while rapamycin facilitated 5-FU-induced p53 protein expression. Using genetic method, Beclin1 overexpression increased while Beclin1 knockdown decreased 5-FU-induced cell proliferation inhibition and apoptosis. Especially, Beclin1 overexpression increased while Beclin1 knockdown decreased 5-FU-induced p53 expression.<bold>Conclusion: </bold>Our study provides both of pharmacological and genetic evidence to support that autophagy facilitates anticancer effect of the chemotherapeutic agent. The associated application of autophagy inducer with 5-FU would be beneficial for the chemotherapy in HCT-116 cancer cells.
- Subjects
AUTOPHAGY; CELL death; FLUOROURACIL; ANTINEOPLASTIC agents; CELL proliferation; GENE expression; RNA metabolism; APOPTOSIS; CELL physiology; CELLS; COLON tumors; DRUG synergism; CLINICAL drug trials; NERVE tissue proteins; PURINES; RECTUM tumors; PHARMACODYNAMICS; RAPAMYCIN
- Publication
Journal of Cancer Research & Therapeutics, 2018, Vol 14, pS1141
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/0973-1482.204898